Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention. Although tamoxifen does increase the risk of uterine cancer, the overall increase in risk is low (less than 1%).
The American Cancer Society is a qualified 501(c)(3) tax-exempt organization.
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication use for the risk reduction of primary breast cancer in women: Updated evidence report and systematic review for the US Preventive Services Task Force. These include serious blood clots and cancer of the uterus.Both tamoxifen and raloxifene increase your risk of developing blood clotsBecause these drugs increase your risk of developing serious blood clots, there is also concern that they might also increase your risk of heart attack or stroke, Drugs could be a lifesaver and in this case, Raloxifene (Raloxifene Hydrochloride) and Tamoxifen (Tamoxifen Citrate) are two drug compounds that have the potential to save lives, especially those lives that breast cancer, postmenopausal osteoporosis and gynecomastia has sought to destroy or at least to make miserable.Both Raloxifene and Tamoxifen belong to a class of medications described as Selective Estrogen Receptor Modulators (SERMs), they are described as such because they have the capacity to be estrogen receptor agonists or antagonists depending on the body tissue it acts on, a short analogy of what SERMs do is presented in the following example; when you bath with Soap, it cleanses the body but if you let it in your eyes or nostrils it will cause pain, the idea? Menstrual periods can become irregular or even stop. Practice Guidelines in Oncology: Breast Cancer Risk Reduction. From basic information about cancer and its causes to in-depth information on specific cancer types – including risk factors, early detection, diagnosis, and treatment options – you’ll find it here.You can help reduce your risk of cancer by making healthy choices like eating right, staying active and not smoking. This condition is not to be mistaken with breast cancer as the lump involved is benign, i.e.
National Comprehensive Cancer Network (NCCN). Tamoxifen can also cause vaginal dryness and vaginal discharge. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Tamoxifen and Raloxifene have not been approved by the FDA specifically for the treatment of gynecomastia but doctors prescribe them off-label as clinical trials have shown them to be effective in the treatment of this condition, medical treatment for gynecomastia is most effective when started within the first two years of symptomatic expressions.
Endometrial cancer is the cancer that affects the endometrium (the uterus lining), symptoms can include pelvic pain and vaginal bleeding unassociated with menstrual period. Cancer.org is provided courtesy of the Leo and Gloria Rosen family. Tamoxifen also comes in a liquid form.
Although tamoxifen may be slightly better than raloxifene at reducing the risk of breast cancer, the risk of blood clots and uterine cancer also are lower with raloxifene.
V.1.2019. This would be only a 2% change overall.Since the change in your overall risk depends on your baseline risk, you would benefit less if you had a lower baseline risk, and you would benefit more if your risk was higher. Both drugs perform an antagonistic function on estrogen receptors in the breast tissue thus giving breast cancer a hard time growing at all.
(See Because tamoxifen acts like estrogen in the uterus, it can increase your risk of Although tamoxifen does increase the risk of uterine cancer, the overall increase in risk is low (less than 1%). SERMs can be estrogenic or anti-estrogenic depending on the target body tissue, Clinical studies have shown that Tamoxifen is estrogenic in the endometrium while Raloxifene is anti-estrogenic and excessive exposure of the endometrium to estrogen is a high risk cancer factor, other high risk cancer factors include high blood pressure, obesity and diabetes, endometrial cancer is known to occur more in women that are postmenopausal, these studies conclude that those under Raloxifene therapy had a significantly lower odd in having endometrial cancer than those under Tamoxifen therapy.Raloxifene and Tamoxifen share similar side effects but mildness or severeness of side effects varies with each drug. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf on July 31, 2019.Visvanathan K, Fabian CJ, Bantug E, et al.
The side effects listed here are not exhaustive, if you experience any sort of discomfort when using either drug, see your doctor immediately.While Tamoxifen (Nolvadex) is specifically approved by the FDA for the prevention and treatment of breast cancer in both men and women and Raloxifene (Evista) is specifically approved by the FDA for treatment of Osteoporosis (soft and brittle bone) which is commonly experienced by post menopausal women, both drugs have a lot in common; they are both orally administered prescription medications, they belong to the same drug class description- SERMs, they also share certain side effects although intensity of side effects vary with either drug.